Alnylam Pharmaceuticals $ALNY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS13
PHASE 3 / 2-35
RECRUITING7
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO25%
Delay Index: of 8 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Alnylam Pharmaceuticals on the live radar map → 📅 $ALNY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Vutrisiran NCT04153149 |
P3 | Active, not recruiting | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | 655 | 2024-05-08 |
| ALN-2232 NCT07463846 |
P1/2 | Recruiting | Obesity | 156 | 2027-04-28 |
| ALN-4324 NCT07465224 |
P2 | Active, not recruiting | Type 2 Diabetes Mellitus (T2DM) | 24 | 2027-05-28 |
| HMBeacon NCT07575308 |
P2 | Recruiting | Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) | 24 | 2027-06-30 |
| cAPPricorn-1 NCT06393712 |
P2 | Active, not recruiting | Cerebral Amyloid Angiopathy | 210 | 2027-08-09 (+1 mo) |
| ALN-4324 NCT06845202 |
P1/2 | Active, not recruiting | Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM) | 105 | 2027-08-31 (+14 mo) |
| TRITON-PN NCT07223203 |
P3 | Recruiting | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN | 125 | 2027-12-27 |
| InsigHHT NCT06659640 |
P1/2 | Active, not recruiting | Hereditary Hemorrhagic Telangiectasia | 89 | 2028-01-05 (+19 mo) |
| Vutrisiran NCT06679946 |
P3 | Enrolling by invitation | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | 700 | 2028-03-31 (-3 mo) |
| ALN-AGT01 RVR NCT07553442 |
P2 | Recruiting | Hypertension | 93 | 2028-04-01 |
| Mivelsiran NCT07636811 |
P2 | Recruiting | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | 58 | 2030-05-18 |
| Nucresiran NCT07052903 |
P3 | Recruiting | Transthyretin Amyloidosis With Cardiomyopathy | 2250 | 2030-05-28 |
| ZENITH NCT07181109 |
P3 | Recruiting | High Risk Cardiovascular Disease; Hypertension | 11000 | 2030-09-23 (-1 mo) |